Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies

Ther Clin Risk Manag. 2014 Aug 16;10:651-64. doi: 10.2147/TCRM.S57509. eCollection 2014.


The advent of exponential growth of novel agents tested and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has brought about a need for understanding of the mechanism of action, side-effects, and clinical efficacy of these drugs as they relate to these patients. This review will provide a synopsis of the treatment landscape in mCRPC as varying agents such as abiraterone acetate, cabazitaxel, sipuleucel-T, radium, and selected emerging agents are presented. A distinct focus on the utilization of enzalutamide, its mechanism of action, key pivotal trials that brought about its US Food and Drug Administration approval, as well as patient-focused perspectives and clinical implications are discussed herein.

Keywords: enzalutamide; metastatic castration-resistant prostate cancer; systemic therapies.

Publication types

  • Review